NCT06746402View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

September 11, 2025

Study Completion Date

September 11, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986278

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

DRUG

Moxifloxacin

Specified dose on specified days

Trial Locations (2)

78209

ICON San Antonio, San Antonio

84124

Local Institution - 0001, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06746402 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants | Biotech Hunter | Biotech Hunter